Related Experiment Video
Updated: May 19, 2026

Increasing Pulmonary Artery Pulsatile Flow Improves Hypoxic Pulmonary Hypertension in Piglets
Published on: May 11, 2015
The Role of the Cellular Communication Network Protein Family in Pulmonary Arterial Hypertension
Carly E Byrd1, Jennifer E Schramm2,3, Jun Yang3
1Department of Pediatrics, Division of Neonatal-Perinatal Medicine Johns Hopkins University Baltimore Maryland USA.
Abstract:
Pulmonary arterial hypertension (PAH) is a complex progressive disease associated with high morbidity and mortality. Circulating serum biomarkers have the potential to optimize diagnosis and prognosis in PAH. The cellular communication network (CCN) protein family is a group of similarly structured matricellular proteins with many roles ranging from fibrosis to malignancy. Individual CCN proteins have been associated with PAH in previous studies, but no study has evaluated multiple CCN proteins as potentially relevant biomarkers in PAH. This study sought to establish associations using the circulating concentrations of measurable CCN proteins and PAH diagnosis, severity, outcomes, and other biomarkers. Serum levels of CCN1, CCN2, CCN3, and CCN6 were measured utilizing 225 patients from the PAH Biobank (PAHBiobank) with available hemodynamic data and 40 control samples. Serum levels of CCN1, 2, 3, and 6 proteins were significantly increased in PAH compared to controls. CCN1, CCN2, and CCN3 were associated with a lower 6-min walk distance. CCN2 and CCN3 were also associated with worse New York Heart Association Functional Class. Higher CCN2 and CCN3 levels correlated with higher levels of Endostatin and NT-proBNP. CCN6 was not significantly associated with any hemodynamic or clinical variables in the PAH cohort. Our results suggest that multiple CCN proteins are increased in PAH and that CCN2 and CCN3 have the most potential as novel biomarkers in PAH.
More Related Videos
Related Concept Videos
Pulmonary Hypertension: Classification and Pathogenesis
There are various classifications for PH, each relating to different underlying causes and also...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Regulation of Angiogenesis and Blood Supply
Transducer Mechanism: Enzyme-Linked Receptors
Major types that are helpful drug targets include:

